Strides Delivers a Robust Q2FY26 with Highest Ever Quarterly EPS Q2FY26 Operational PAT at ₹1,403m and EPS at ₹15.2, Grew 84% YoY

November 6, 2025 Comments (0) 2 Mins Read

Author: Aditya Pareek | EQMint | Press Releases

Bangalore – November 6th 2025 – Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) today announced its consolidated financial results for the quarter (Q2FY26) and half year (H1FY26) ended September 30, 2025.

Q2FY2026 Performance Highlights

Revenue at ₹12,208m, grew 4.6% YoY

Absolute gross margin at ₹7,056m, grew 14.6% YoY

Gross margin improved to 57.8%, up 500bps YoY

EBITDA grew 25.4% YoY to ₹2,316m, EBITDA margin at 19.0%, grew 320bps YoY

Other Regulated Markets revenue at $44m, delivered strong growth of 16% YoY

Operational PAT at ₹1,403m, Grew 84.3% YoY

Operational EPS at ₹15.2

Reported PAT at ₹1,315m

Badree Komandur, MD & Group CEO, commented on the performance and said, “Strides continues to deliver a strong performance in Q2FY26, with growth primarily driven by the Other Regulated Markets. Our focus on profitability enabled the gross margin growth of 15% YoY, and EBITDA growth of 25% YoY.

Operational PAT stood at ₹1,403m, up 84% YoY, with EPS rising to ₹15.2 for the quarter. Net debt reduced sequentially by ₹469m despite currency headwinds and ongoing capex investments, reaffirming our strong financial discipline and focus on balance sheet health.

This performance demonstrates our consistent execution as we continue to invest in sustainable, long-term growth.”

About Strides

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR).

The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donor- funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York).

The Company focuses on “difficult to manufacture” products sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com.

For more such news and information visit EQMint.

Disclaimer: This article is based on information available from public sources. It has not been reported by EQMint journalists. EQMint has compiled and presented the content for informational purposes only and does not guarantee its accuracy or completeness. Readers are advised to verify details independently before relying on them.